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ANALYSIS OF CORONA VIRUS PROTEASE INHIBITORS AS 
POTENTIAL THERAPEUTICS 
Katherine Houser and Susan Baker* 
Biology Department, Illinois Wesleyan University 
Department of Microbiology and Immunology, Loyola University 
SARS-HCoV, or Severe Acute Respiratory Syndrome, is a novel human coronavirus that 
appeared within China in 2003. To date there are no vaccines or antiviral drugs able to either 
halt or prevent an infection by the virus. As part of an ongoing study, experiments were 
designed to develop and assess broad-spectrum antiviral drugs against several human and murine 
coronaviruses. The research involved testing antiviral drugs against the mouse coronavirus 
MHV. These drugs, which were composed of branched organic compounds, targeted the active 
site of one of the two proteases of the murine coronavirus, 3CLPro, halting the enzymatic 
activity resulting in viral inhibition. The drugs had already been proven effective in purified 
protease samples, but had yet to be tested in l iving cells. Thirty-five drugs were tested, and 
while twenty-two displayed no viral inhibition and five exhibited cell toxicity, eight drugs were 
shown to strongly inhibit viral replication. The drugs that were found to be effective at 
inhibiting the viral replication will continue on to be tested against SARS-HCoV in the Biosafety 
Level 3 lab at UIC. The effective drugs were also used further in order to screen for drug 
resistant variants of the virus. These mutants can then be sequenced so that the drugs can be 
improved and the resistance avoided. 
